We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immunomedics Completes Enrollment In Cancer Drug Study
Read MoreHide Full Article
Immunomedics, Inc. announced that a single-arm phase II study on pipeline candidate IMMU-132 (sacituzumab govitecan) has achieved the planned enrollment of 100 patients suffering from metastatic triple-negative breast cancer (TNBC) who have received more than one prior therapy for their metastatic disease.
Immunomedics’ share price has outperformed the Zacks classified Medical - Biomedical and Genetics industry in 2016. The stock gained 18.9% compared with a decline of 26.1% for the industry.
With the trial progressing as planned, the company is preparing to submit a Biological License Application (BLA) to the FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in mid-2017.
Immunomedics also plans to present interim results from phase II trials on IMMU-132 for patients with urinary bladder cancer in Feb 2017. The company is also likely to initiate a phase III confirmatory trial in TNBC in early 2017.
We remind investors that IMMU-132 enjoys Breakthrough Therapy Designation in the U.S. for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease.
Meanwhile, the company is looking for licensing and other strategic activities with regard to IMMU-132 and other clinical and preclinical pipeline candidates.
Immunomedics, a clinical-stage biopharmaceutical company, has built a pipeline of eight candidates. The pipeline includes antibody-drug conjugates (ADCs) as well. The most advanced ADCs are IMMU-132 and labetuzumab govitecan (IMMU-130). Both the candidates are in phase II trials.
Notably, Immunomedics has research collaboration with Bayer AG (BAYRY - Free Report) to study epratuzumab as a thorium-227-labeled antibody.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 in the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 88.3% year to date.
Vanda’s loss estimates for 2016 narrowed from 62 cents to 45 cents, while its earnings estimates for 2017 decreased from 13 cents to 9 cents in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 72.9% year to date.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Immunomedics Completes Enrollment In Cancer Drug Study
Immunomedics, Inc. announced that a single-arm phase II study on pipeline candidate IMMU-132 (sacituzumab govitecan) has achieved the planned enrollment of 100 patients suffering from metastatic triple-negative breast cancer (TNBC) who have received more than one prior therapy for their metastatic disease.
Immunomedics’ share price has outperformed the Zacks classified Medical - Biomedical and Genetics industry in 2016. The stock gained 18.9% compared with a decline of 26.1% for the industry.
With the trial progressing as planned, the company is preparing to submit a Biological License Application (BLA) to the FDA for accelerated approval for IMMU-132 for patients with metastatic TNBC in mid-2017.
Immunomedics also plans to present interim results from phase II trials on IMMU-132 for patients with urinary bladder cancer in Feb 2017. The company is also likely to initiate a phase III confirmatory trial in TNBC in early 2017.
We remind investors that IMMU-132 enjoys Breakthrough Therapy Designation in the U.S. for the treatment of patients with triple-negative breast cancer who have failed at least two prior therapies for metastatic disease.
Meanwhile, the company is looking for licensing and other strategic activities with regard to IMMU-132 and other clinical and preclinical pipeline candidates.
Immunomedics, a clinical-stage biopharmaceutical company, has built a pipeline of eight candidates. The pipeline includes antibody-drug conjugates (ADCs) as well. The most advanced ADCs are IMMU-132 and labetuzumab govitecan (IMMU-130). Both the candidates are in phase II trials.
Notably, Immunomedics has research collaboration with Bayer AG (BAYRY - Free Report) to study epratuzumab as a thorium-227-labeled antibody.
IMMUNOMEDICS Price and Consensus
IMMUNOMEDICS Price and Consensus | IMMUNOMEDICS Quote
Immunomedics currently carries a Zacks Rank #3 (Hold).
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector include Heska Corp. and Vanda Pharmaceuticals (VNDA - Free Report) . Both of them sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 in the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 88.3% year to date.
Vanda’s loss estimates for 2016 narrowed from 62 cents to 45 cents, while its earnings estimates for 2017 decreased from 13 cents to 9 cents in the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 72.9% year to date.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>